Stroke Prevention in Atrial Fibrillation

In This Section:

◄

Clinical publications

Guidelines

Opinion Articles

Radcliffe Content

Review Articles

Trials

►

Stroke Prevention in Atrial Fibrillation

Despite the evidence-based guidelines for the management of atrial fibrillation (AF), serious gaps continue to exist between clinical knowledge and practice, leaving patients at risk for disabling strokes. It is estimated that up to 67% of AF-related strokes are preventable. The significant increase in mortality and functional impairment is even more alarming, compared to non-AF strokes.

Updated AF treatment guidelines recommend new oral anticoagulants (NOACs) over warfarin for stroke prevention except, in patients with moderate to severe mitral stenosis or a mechanical heart valve. Based on some recent trials, NOACs were superior to warfarin for the prevention of the composite of stroke and systemic embolism in patients with AF and an additional risk factor for stroke. Reversal agents are now also available for NOACs in patients for severe bleeding or emergency procedures.

With the increased utilization of NOACs, it is critical for the clinician to understand the clinical and practical usage of these agents in diverse patient populations and clinical situations.

See more ▼

Close X

Recent Videos

Video Series

Embracing New Approaches in Long-Standing Persistent Atrial Fibrillation

Adrian Pick, Emily Kotschet, Andrea Russo, et al

Watch time: 1h 31m 10s (7 videos)

Broadcast

Use of the DiamondTemp™ System in Atrial and Ventricular Procedures

Philipp Sommer, Christian Sohns, Dipen Shah, et al

Watch time: 1h 33s

Video Series

EHRA 2022: Late-Breaking Science Video Collection

Jose L Merino, Jason G Andrade, Dhiraj Gupta, et al

Watch time: 22m 38s (6 videos)

Clinical publications

Two‐year outcomes with a next‐generation left atrial appendage device: final results of the PINNACLE FLX trial

Doshi SK, Kar S, Sadhu A, et al. J Am Heart Assoc 2023;12:e026295.

Association of neighborhood disadvantage and anticoagulation for patients with atrial fibrillation in the Veterans Health Administration: the REACH-AF Study

McDermott A, Kim N, Hausmann LRM, et al. J Gen Intern Med 2023;38:848–56.

Real-world clinical outcomes with a next-generation left atrial appendage closure device: the FLXibility Post-Approval Study

Betts TR, Grygier M, Kudsk JEN, et al. Europace 2023;25:914–21.

Electrocardiographic markers of subclinical atrial fibrillation detected by implantable loop recorder: insights from the LOOP Study

Xing LY, Diederichsen SZ, Højberg S, et al. Europace 2023;25:euad014.

Fully digital self-screening for atrial fibrillation with patch electrocardiogram

Sandberg EL, Halvorsen S, Berge T, et al. Europace 2023;25:euad075.

Outcomes of early rhythm control therapy in patients with atrial fibrillation and a high comorbidity burden in large real-world cohorts

Dickow J, Kany S, Cardoso VR, et al. Circ Arrhythm Electrophysiol 2023;16:e011585.

Morbid obesity is associated with increased procedural complications and worse in-hospital outcomes after percutaneous left atrial appendage occlusion device implantation

Agarwal S, Asad ZUA, Khan MZ, et al. Heart Rhythm 2023;20:637–9.

Contemporary trends in utilization and outcomes of percutaneous left atrial appendage occlusion in the United States from 2016 to 2019

Gupta M, Minhas AMK, Goel SS, et al. Heart Rhythm 2023;20:313–4.

Early stroke and mortality after percutaneous left atrial appendage occlusion in patients with atrial fibrillation

Kogan EV, Sciria CT, Liu CF, et al. Stroke 2023;54:947–54.

Improved prognosis with integrated care management including early rhythm control and healthy lifestyle modification in patients with concurrent atrial fibrillation and diabetes mellitus: a nationwide cohort study

Lee SR, Ahn HJ, Choi EK, et al. Cardiovasc Diabetol 2023;22:18.

Benefit and harm of anticoagulation in the prevention of thromboembolic stroke for non-valvular atrial fibrillation in haemodialysis patients: a Top End of Northern Australia study

Xu C, Abeyaratne A, Wong YHS, Majoni SW. Intern Med J 2023;53:517–24.

Oral anticoagulants and the risk of dementia in patients with nonvalvular atrial fibrillation: a population-based cohort study

Rahman AA, Michaud J, Dell’Aniello S, et al. Neurology 2023;100:e1309–20.

Cardiorenal outcomes among patients with atrial fibrillation treated with oral anticoagulants

Trevisan M, Hjemdahl P, Clase CM, et al. Am J Kidney Dis 2023;81:307–17.e1.

Peridevice leak after left atrial appendage occlusion: incidence, mechanisms, clinical impact, and management

Alkhouli M, Backer OD, Ellis CR, et al. JACC Cardiovasc Interv 2023;16:627–42.

Intracardiac echocardiography to guide Watchman FLX implantation: the ICE LAA study

Nielsen-Kudsk JE, Berti S, Caprioglio F, et al. JACC Cardiovasc Interv 2023;16:643–51.

Atrial fibrillation risk assessment after embolic stroke of undetermined source

von Falkenhausen AS, Feil K, Sinner MF, et al. Ann Neurol 2023;93:479–88.

Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study

Lawal OD, Aronow HD, Shobayo F, et al. Circulation 2023;147:782–94.

Comparative effectiveness of left atrial appendage occlusion versus oral anticoagulation by sex

Zeitler EP, Kearing S, Coylewright M, et al. Circulation 2023;147:586–96.

Time trends in patient characteristics, anticoagulation treatment, and prognosis of incident nonvalvular atrial fibrillation in the Netherlands

Chen Q, Toorop MMA, Tops LF, et al. JAMA Netw Open 2023;6:e239973.

Comparative effectiveness and safety of oral anticoagulants by dementia status in older patients with atrial fibrillation

Lin KJ, Singer DE, Bykov K, et al. JAMA Netw Open 2023;6:e234086.

Association of race and ethnicity with oral anticoagulation and associated outcomes in patients with atrial fibrillation: findings from the get with the guidelines-atrial fibrillation registry

Essien UR, Chiswell K, Kaltenback LA, et al. JAMA Cardiol 2022;7:1207–17.

Predictors of atrial fibrillation in patients with stroke attributed to large- or small-vessel disease: a prespecified secondary analysis of the STROKE AF randomized clinical trial

Schwamm LH, Kamel H, Granger CB, et al. JAMA Neurol 2023;80:99–103.

Severity and etiology of incident stroke in patients screened for atrial fibrillation vs usual care and the impact of prior stroke: a post hoc analysis of the LOOP randomized clinical trial

Diederichsen SZ, Frederiksen KS, Xing LY, et al. JAMA Neurol 2022;79:997–1004.

Early rhythm control therapy for atrial fibrillation in low-risk patients: a nationwide propensity score-weighted study

Kim D, Yang PS, You SC, et al. Ann Intern Med 2022;175:1356–65.

Apixaban versus rivaroxaban in patients with atrial fibrillation and valvular heart disease : a population-based study

Dawwas GK, Cuker A, Barnes GD, et al. Ann Intern Med 2022;175:1506–14.

Qualitative analysis of patient-physician discussions regarding anticoagulation for atrial fibrillation

Martinez KA, Hurwitz HM, Rothberg MB. JAMA Intern Med 2022;182:1260–6.

Refractory cardiogenic shock in a senile atrial fibrillation patient after left atrial appendage occlusion

Xiao Q, Pu X, Wei X, Chen M. Eur Heart J 2022;43:4663.

Bleeding and ischaemic events after first bleed in anticoagulated atrial fibrillation patients: risk and timing

Meyre PB, Blum S, Hennings E, et al. Eur Heart J 2022;43:4899–908.

Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study

Komen JJ, Pottegård A, Mantel-Teeuwisse AK, et al. Eur Heart J 2022;43:3528–38.

Cost-effectiveness of population screening for atrial fibrillation: the STROKESTOP study

Lyth J, Svennberg E, Bernfort L, et al. Eur Heart J 2023;44:196–204.

High frequency of anticoagulation management errors preceding ischaemic strokes in atrial fibrillation

Wong E, Aaqib M, Thijs V. Intern Med J 2022;52:1024–8.

Geographic and temporal variation in the treatment and outcomes of atrial fibrillation: a population-based analysis of national quality indicators

Chew DS, Au F, Xu Y, et al. CMAJ Open 2022;10:E702–13.

Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation

Pol T, Hijazi Z, Lindbäck J, et al. Cardiovasc Res 2022;118:2112–23.

Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation

Polymeris AA, Meinel TR, Oehler H, et al. J Neurol Neurosurg Psychiatry 2022;93:588–98.

Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: a cohort study

Ajabnoor AM, Zghebi SS, Parisi R, et al. PLoS Med 2022;19:e1004003.

Trends and risk factors associated with stroke recurrence in China, 2007-2018

Xu J, Zhang X, Jin A, et al. JAMA Netw Open 2022;5:e2216341.

Antithrombotic therapy after left atrial appendage occlusion in patients with atrial fibrillation

Freeman JV, Higgins AY, Wang Y, et al. J Am Coll Cardiol 2022;79:1785–98.

Elevated lipoprotein(a) and risk of atrial fibrillation: an observational and Mendelian randomization study

Mohammadi-Shemirani P, Chong M, Narula S, et al. J Am Coll Cardiol 2022;79:1579–90.

Presenting pattern of atrial fibrillation and outcomes of early rhythm control therapy

Goette A, Borof K, Breithardt G, et al. J Am Coll Cardiol 2022;80:283–95.

Risk levels and adverse clinical outcomes among patients with nonvalvular atrial fibrillation receiving oral anticoagulants

Lip GYH, Murphy RR, Sahiar F, et al. JAMA Netw Open 2022;5:e2229333.

Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study

Nosáľ V, Petrovičová A, Škorňová I, et al. Eur J Clin Pharmacol 2022;78:557–64.

Early anticoagulation in atrial fibrillation-related acute ischaemic stroke: efficacy and safety profile

Matos-Ribeiro J, Castro-Chaves P, Oliveira-Ferreira M, et al. J Neurol 2022;269:2099–112.

Electronic alerts to initiate anticoagulation dialogue in patients with atrial fibrillation

Gutierrez JA, Christian RT, Aday AW, et al. Am Heart J 2022;245:29–40.

Antithrombotic therapy for patients with atrial fibrillation and bioprosthetic valves　― real-world data from the multicenter, prospective, observational BPV-AF Registry ―

Izumi C, Miyake M, Fujita T, et al. Circ J 2022;86:440–8.

Additional effects of antiplatelet therapy on anticoagulant agents in patients with bioprosthetic valves and atrial fibrillation

Amano M, Miyake M, Kitai T, et al. Circ J 2022;86:415–24.

10-year trends of antithrombotic therapy status and outcomes in Japanese atrial fibrillation patients　― the Fushimi AF Registry ―

Akao M, Ogawa H, Masunaga N, et al. Circ J 2022;86:726–36.

Assessment of adherence, treatment satisfaction and knowledge of direct oral anticoagulants in atrial fibrillation patients

Moudallel S, van Laere S, Cornu P, et al. Br J Clin Pharmacol 2022;88:2419–29.

Geriatric conditions do not predict stroke or bleeding in long-term care residents with atrial fibrillation

Kapoor A, Patel J, Chen Z, et al. J Am Geriatr Soc 2022;70:1218–27.

Adherence is an optimal factor for maximizing the effective and safe use of oral anticoagulants in patients with atrial fibrillation

Yang SY, Kang DW, Nam JH, et al. Sci Rep 2022;12:3413.

Rhythm control without catheter ablation may have benefits beyond stroke prevention in rivaroxaban-treated non-permanent atrial fibrillation

Chiou WR, Lin PL, Huang CC, et al. Sci Rep 2022;12:3745.

Real world data of anticoagulant treatment in non-valvular atrial fibrillation across renal function status

Calderon JM, Martinez F, Fernandez A, et al. Sci Rep 2022;12:6123.

Association between inappropriately dosed anticoagulation therapy with stroke severity and outcomes in patients with atrial fibrillation

Vinding NE, Butt JH, Olesen JB, et al. J Am Heart Assoc 2022;11:e024402.

Global oral anticoagulation use varies by region in patients with recent diagnosis of atrial fibrillation: the GLORIA‐AF Phase III registry

Bayer V, Kotalczyk A, Kea B, et al. J Am Heart Assoc 2022;11:e023907.

Post‐intracranial hemorrhage antithrombotic therapy in patients with atrial fibrillation

Lin SY, Chang YC, Lin FJ, et al. J Am Heart Assoc 2022;11:e022849.

Oral anticoagulant treatment and the risk of dementia in patients with atrial fibrillation: a population‐based cohort study

Bezabhe WM, Bereznicki LR, Radford J, et al. J Am Heart Assoc 2022;11:e023098.

Left atrial mechanics for secondary prevention from embolic stroke of undetermined source

Sade LE, Keskin S, Can U, et al. Eur Heart J Cardiovasc Imaging 2022;23:381–91.

Genetic architecture of stroke of undetermined source: overlap with known stroke etiologies and associations with modifiable risk factors

Georgakis MK, Parodi L, Frerich S, et al. Ann Neurol 2022;91:640–51.

Cost-effectiveness analysis of left atrial appendage occlusion in patients with atrial fibrillation and contraindication to oral anticoagulation

Labori F, Persson J, Bonander C, et al. Eur Heart J 2022;43:1348–56.

Monitoring of direct oral anticoagulants plasma levels for secondary stroke prevention

Siedler G, Macha K, Stoll S, et al. J Thromb Haemost 2022;20:1138–45.

Prevalence of frailty and associations with oral anticoagulant prescribing in atrial fibrillation

Sanghai SR, Liu W, Wang W, et al. J Gen Intern Med 2022;37:730–6.

Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry

Huisman MV, Teutsch C, Lu S, et al. Clin Res Cardiol 2022;111:548–59.

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

Lip GYH, Kotalczyk A, Teutsch C, et al. Clin Res Cardiol 2022;111:560–73.

Guidelines

Participation by patients from low- and middle-income countries (LMICs) in trial evidence supporting secondary stroke prevention guideline recommendations

Opare-Addo PA, Sarfo FS, Berchie PO, et al. J Neurol Sci 2023;448:120641.

Leap or lag: left atrial appendage closure and guidelines

Camm AJ. Europace 2023;25:euad067.

Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference

Schnabel RB, Marinelli EA, Arbelo E, et al. Europace 2023;25:6–27.

SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure

Saw J, Holmes DR, Cavalcante JL, et al. Heart Rhythm 2023;20:e1–16.

Oral anticoagulant use in patients with atrial fibrillation and chronic kidney disease: a review of the evidence with recommendations for Australian clinical practice

Hammett C, Badve SV, Kerr PG, et al. Heart Lung Circ 2022;31:1604–11.

Management of atrial fibrillation: two decades of progress — a scientific statement from the European Cardiac Arrhythmia Society

Lévy S, Steinbeck G, Santini L, et al. J Interv Card Electrophysiol 2022;65:287–326.

Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 update by the ESC Working Group on Thrombosis

Andreotti F, Geisler T, Collet JP, et al. Eur Heart J 2023;44:262–79.

Heart Rhythm Society Atrial Fibrillation Centers of Excellence study: a survey analysis of stakeholder practices, needs, and barriers

Sandhu RK, Seiler A, Johnson CJ, et al. Heart Rhythm 2022;19:1039–48.

Analysis of the ESC/EACTS 2020 atrial fibrillation guidelines with perioperative implications

Nelson JA, Gue YX, Christensen JM, et al. J Cardiothorac Vasc Anesth 2022;36:2177–95.

The 2020 ESC atrial fibrillation guidelines for atrial fibrillation catheter ablation, CABANA, and EAST

Arbelo E, Dagres N. Europace 2022;24(Supplement_2):ii3–7.

2019 Chinese expert consensus statement on left atrial appendage closure in patients with atrial fibrillation

Ben H, Changsheng M, Shulin W. Pacing Clin Electrophysiol 2022;45:535–55.

Time trends in adherence to guideline recommendations for anticoagulation therapy in patients with atrial fibrillation and myocardial infarction

Jortveit J, Sandberg EL, Pripp AH, Halvorsen S. Open Heart 2022;9:e001934.

P wave parameters and indices: a critical appraisal of clinical utility, challenges, and future research

Chen LY, Ribeiro ALP, Platonov PG, et al. Circ Arrhythm Electrophysiol 2022;15:e010435.

Opinion Articles

A comparison of atrial fibrillation detection strategies after ischemic stroke-a retrospective study

Salehin S, Muhammad S, Rasmussen P, et al. Curr Probl Cardiol 2023;48:101515.

Embolic stroke of undetermined source: current perspectives on diagnosis, investigations, and management

Field TS, Sposato LA, Hill MD, et al. Can J Cardiol 2023;39:172–86.

Racial and ethnic disparities in stroke prevention for atrial fibrillation

Calvert P, Tamirisa K, Al-Ahmad A, et al. Am J Med 2023;136:225–33.

Research opportunities in stroke prevention for atrial fibrillation: a report from a national heart, lung, and blood institute virtual workshop

Go AS, Al-Khatib SM, Desvigne-Nickens P, et al. Stroke 2023;54:e75–85.

Antithrombotic management after left atrial appendage closure: current evidence and future perspectives

Mesnier J, Cepas-Guillén P, Freixa X, et al. Circ Cardiovasc Interv 2023;16:e012812.

Large-scale digital population screening for atrial fibrillation: swinging around the uncertainties

Vardas PE. Cardiovasc Res 2023;119:e120–1.

Atrial fibrillation and stroke: a review and new insights

Escudero-Martínez I, Morales-Caba L, Segura T. Trends Cardiovasc Med 2023;33:23–9.

Anticoagulation for stroke prevention in atrial fibrillation

Krepostman N, Kramer HJ. Am J Kidney Dis 2022;80:561–3.

Left atrial appendage occluders-new hope for stroke prevention in high-risk patients

Osmancik P, Widimsky P. Eur Heart J 2022;43:4669–71.

Screening for atrial fibrillation to prevent stroke: increasing enthusiasm but outcomes still lag

Spatz ES, Herrin J. Eur Heart J 2023;44:205–7.

Atrial fibrillation and stroke: who is low risk and what are we going to do about it?

McIntyre WF, Linz D. Eur Heart J 2022;43:3539–41.

Safety of non-vitamin K antagonist oral anticoagulants: concerns in patients with atrial fibrillation and glomerular hyperfiltration?

Huqi A, Zoccali C, Giugliano RP, De Caterina R. Eur Heart J 2023;44:322–5.

Atrial fibrillation — what is it and how is it treated?

Antman EM, Leopold JA, Sauer WH, Zei PC. N Engl J Med 2022;387:e38.

JCS/JHRS guideline: rivaroxaban not recommended for patients with nonvalvular atrial fibrillation and high bleeding risk　― reply ―

Ono K, Iwasaki Y, Shimizu W. Circ J 2022;86:1205.

JCS/JHRS guideline: rivaroxaban not recommended for patients with nonvalvular atrial fibrillation and high bleeding risk

Hirayama A, Tanahashi N, Tachiiri M, Hayasaki T. Circ J 2022;86:1204.

Worldwide trends in antithrombotic therapy prescribing for atrial fibrillation: observations on the 'transition era' to non-vitamin K antagonist oral anticoagulants

Ritchie LA, Lane DA, Lip GYH. Europace 2022;24:871–3.

CHA2DS2-VASc score is no longer enough—authors' reply

Noubiap JJ, Middeldorp ME, Thomas G, Sanders P. Europace 2022;24:1195.

CHA2DS2-VASc is no longer enough

Reiffel JA. Europace 2022;24:1195.

The Atrial Fibrillation Heart Team—guiding therapy in left atrial appendage occlusion with increasingly complex patients and little evidence

Kany S, Metzner A, Lubos E, Kirchhof P. Eur Heart J 2022;43:1691–2.

Letter by Price et al regarding the article, "Amplatzer Amulet Left Atrial Appendage Occluder versus Watchman device for stroke prophylaxis (Amulet IDE): a randomized, controlled trial"

Price MJ, Gibson DN, Kar S. Circulation 2022;145:e849.

Letter by Natale et al regarding article, "Amplatzer Amulet Left Atrial Appendage Occluder versus Watchman device for stroke prophylaxis (Amulet IDE): a randomized, controlled trial"

Natale A, Kar S, Holmes D. Circulation 2022;145:e847–8.

Letter by Dhruva and Redberg regarding article, "Amplatzer Amulet Left Atrial Appendage Occluder versus Watchman device for stroke prophylaxis (Amulet IDE): a randomized, controlled trial”

Dhruva SS, Redberg RF. Circulation 2022;145:e845–6.

Preventing stroke in atrial fibrillation patients

Nicholls M. Eur Heart J 2022;43:2001–2.

Use of anticoagulant therapy in patients with acute myocardial infarction and atrial fibrillation

Lasica R, Djukanovic L, Popovic D, et al. Medicina (Kaunas) 2022;58:338.

Left atrial appendage exclusion in patients with atrial fibrillation: should it become standard of care?

Sarris-Michopoulos P, Magarakis M. J Card Surg 2022;37:1139–41.

Are 2 left atrial appendage guards better than 1? The Amulet IDE randomized trial

Kowalewski C, Dagres N, Hindricks G. Circulation 2022;145:739–41.

Rivaroxaban vs apixaban and ischemic or hemorrhagic events in patients with atrial fibrillation—reply

Ray WA, Murray KT. JAMA 2022;327:1290.

Rivaroxaban vs apixaban and ischemic or hemorrhagic events in patients with atrial fibrillation

Gu HQ. JAMA 2022;327:1290.

Direct oral anticoagulants across the heart failure spectrum: the precision medicine era

Paolillo S, Ruocco G, Filardi PP, et al. Heart Fail Rev 2022;27:135–45.

Heartbeat: lower risk of dementia with a direct oral anticoagulatant, compared to a vitamin K antagonist, for patients with atrial fibrillation

Otto CM. Heart 2021;107:1847–9.

Insufficient use of anticoagulation for frail patients with atrial fibrillation: still stuck in the "early majority" phase

Gula LJ, Skanes AC. Can J Cardiol 2022;38:9–10.

It's time to rethink (and retrial) our framework for stroke prevention in atrial fibrillation

Turakhia MP. JAMA Cardiol 2021;6:1370.

Impact of a patient's baseline risk on the relative benefit and harm of a preventive treatment strategy: applying trial results in clinical decision making

de Vries TI, Stam-Slob MC, Peters RJG, et al. J Am Heart Assoc 2022;11:e017605.

In patients with recently diagnosed atrial fibrillation, think anticoagulation and rhythm control

Kirchhof P. Circulation 2021;144:1587–9.

Embolic stroke of undetermined source: can we identify subgroups with high risk for atrial fibrillation who may benefit from oral anticoagulation?

Hankey GJ. Circulation 2021;144:1747–9.

Screening for atrial fibrillation—more data still needed

Greenland P. JAMA 2022;327:329–30.

Radcliffe Content

Percutaneous Left Atrial Appendage Occlusion: What the Practising Physician Should Know

European Cardiology Review 2023;18:e57

Transcatheter Left Atrial Appendage Closure: Devices Available, Pitfalls, Advantages, and Future Directions

US Cardiology Review 2023;17:e05.

Detection of Atrial Fibrillation in Patients Admitted with Ischaemic Stroke: A Non-systematic Review of the Asian Population

Journal of Asian Pacific Society of Cardiology 2023;2:e04.

‘Pill-in-the-pocket’ Oral Anticoagulation Guided by Daily Rhythm Monitoring for Stroke Prevention in Patients with AF: A Systematic Review and Meta-analysis

Arrhythmia & Electrophysiology Review 2023;12:e05.

Review Articles

Protocol for a systematic review and individual participant data meta-analysis of randomized trials of screening for atrial fibrillation to prevent stroke

AF SCREEN and AFFECT-EU Collaborators. Thromb Haemost 2023;123:366–76.

Atrial fibrillation detection and management in hypertension

Gawałko M, Linz D. Hypertension 2023;80:523–33.

Oral anticoagulation in patients with advanced chronic kidney disease and atrial fibrillation: beyond anticoagulation

Dhaese SAM, De Vriese AS. Mayo Clin Proc 2023;98:750–70.

Comparison of efficacy and safety of direct oral anticoagulants and warfarin between patients in Asian and non-Asian regions: a systematic review and meta-regression analysis

Ambe K, Akita A, Wei J, et al. Clin Pharmacol Ther 2023;113:1240–50.

Nonthrombogenic roles of the left atrial appendage: JACC review topic of the week

Alkhouli M, Di Biase L, Natale A, et al. J Am Coll Cardiol 2023;81:1063–75.

Postoperative atrial fibrillation: from mechanisms to treatment

Gaudino M, Di Franco A, Rong LQ, et al. Eur Heart J 2023;44:1020–39.

Effectiveness and safety of antithrombotic medication in patients with atrial fibrillation and intracranial hemorrhage: systematic review and meta-analysis

Ivany E, Ritchie LA, Lip GYH, et al. Stroke 2022;53:3035–46.

Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials

Benz AP, Johansson I, Dewilde WJM, et al. Eur Heart J Cardiovasc Pharmacother 2022;8:648–59.

Efficacy and safety of novel oral anticoagulants in patients with atrial nonvalvular atrial fibrillation and diabetes mellitus: a systematic review and meta-analysis

Jia X, Yin Z, Zhang W, et al. J Transl Med 2022;20:441.

Contemporary oral anticoagulant therapy of patients with atrial fibrillation in China: status, obstacles, and strategies for improvement

Shang L, Zhang Y, Zhao Y, et al. Biosci Trends 2022;16:317–29.

Impact of frailty models on the prescription of oral anticoagulants and on the incidence of stroke, bleeding, and mortality in older patients with atrial fibrillation: a systematic review

Presta R, Brunetti E, Polidori MC, Bo M. Ageing Res Rev 2022;82:101761.

Consumer-led screening for atrial fibrillation: Frontier review of the AF-SCREEN International Collaboration

Brandes A, Stavrakis S, Freedman B, et al. Circulation 2022;146:1461–74.

Thromboprophylaxis in patients with Fontan circulation

Van den Eynde J, Possner M, Alahdab F, et al. J Am Coll Cardiol 2023;81:374–89.

Long-term cardiac monitoring after embolic stroke of undetermined source: search longer, look harder

Sagris D, Harrison SL, Buckley BJR, et al. Am J Med 2022;135:e311–7.

In search of the optimal antithrombotic regimen for intracerebral hemorrhage survivors with atrial fibrillation

Peng TJ, Viscoli C, Khatri P, et al. Drugs 2022;82:965–77.

Acute ischemic stroke, depressed left ventricular ejection fraction, and sinus rhythm: prevalence and practice patterns

Baker AD, Schwamm LH, Sanborn DY, et al. Stroke 2022;53:1883–91.

Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis

Alon L, Corica B, Raparelli V, et al. Eur J Prev Cardiol 2022;29:938–46.

Managing thrombotic risk in patients with diabetes

Camm AJ, Sabbour H, Schnell O, et al. Cardiovasc Diabetol 2022;21:160.

Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis

Thangjui S, Kewcharoen J, Yodsuwan R, et al. Eur Heart J Cardiovasc Pharmacother 2022;8:325–35.

Direct oral anticoagulants in atrial fibrillation following cardiac surgery: a systematic review and meta-analysis with trial sequential analysis

Koh KK, Ling RR, Tan SYS, et al. Br J Anaesth 2022;129:154–62.

Efficacy and safety considerations with dose-reduced direct oral anticoagulants: a review

Bikdeli B, Tajrishi FZ, Sadeghipour P, et al. JAMA Cardiol 2022;7:747–59.

The increasing role of rhythm control in patients with atrial fibrillation: JACC state-of-the-art review

Camm AJ, Naccarelli GV, Mittal S, et al. J Am Coll Cardiol 2022;79:1932–48.

Strategies for maintaining brain health: the role of stroke risk factors unique to elderly women

Manwani B, Finger C, Lisabeth L. Stroke 2022;53:2662–72.

A review of direct oral anticoagulants in patients with stage 5 or end-stage kidney disease

Starr JA, Pinner NA, Mannis M, Stuart MK. Ann Pharmacother 2022;56:691–703.

Non-vitamin K oral anticoagulants versus vitamin K antagonists in post transcatheter aortic valve replacement patients with clinical indication for oral anticoagulation: a meta-analysis

Chen YF, Liu F, Li XW, et al. Clin Cardiol 2022;45:401–6.

Comparison of the efficacy and safety of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation and concomitant liver cirrhosis: a systematic review and meta-analysis

Lee ZY, Suah BH, Teo YH, et al. Am J Cardiovasc Drugs 2022;22:157–65.

Decision aids for shared decision-making and appropriate anticoagulation therapy in patients with atrial fibrillation: a systematic review and meta-analysis

Song D, Zhou J, Fan T, et al. Eur J Cardiovasc Nurs 2022;21:97–106.

Meta-analysis comparing apixaban versus rivaroxaban for management of patients with nonvalvular atrial fibrillation

Mamas MA, Batson S, Pollock KG, et al. Am J Cardiol 2022;166:58–64.

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain

Escobar Cervantes C, Martí-Almor J, Cabeza AIP, et al. PLoS One 2022;17:e0266658.

Sepsis-driven atrial fibrillation and ischaemic stroke. Is there enough evidence to recommend anticoagulation?

Induruwa I, Hennebry E, Hennebry J, et al. Eur J Intern Med 2022;98:32–6.

Adherence to the 'Atrial Fibrillation Better Care' pathway in patients with atrial fibrillation: impact on clinical outcomes—a systematic review and meta-analysis of 285,000 patients

Romiti GF, Pastori D, Rivera-Caravaca JM, et al. Thromb Haemost 2022;122:406–14.

Utility of the CHA2DS2-VASc score for predicting ischaemic stroke in patients with or without atrial fibrillation: a systematic review and meta-analysis

Siddiqi TJ, Usman MS, Shahid I, et al. Eur J Prev Cardiol 2022;29:625–31.

Cardiovascular complications of interatrial conduction block: JACC state-of-the-art review

Power DA, Lampert J, Camaj A, et al. J Am Coll Cardiol 2022;79:1199–211.

Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum

Lüscher TF, Davies A, Beer JH, et al. Eur Heart J 2022;43:940–58.

Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation who underwent bioprosthetic valve replacement

Shaikh S, Mohamed MMG, Osman M, Kheiri B. Am J Cardiol 2022;169:148–9.

Extended venous thromboprophylaxis in patients hospitalized for acute ischemic stroke: a systematic review and meta-analysis

Valeriani E, Potere N, Candeloro M, et al. Eur J Intern Med 2022;95:80–6.

Anticoagulants for stroke prevention in heart failure with reduced ejection fraction

Schäfer A, Flierl U, Bauersachs J. Clin Res Cardiol 2022;111:1–13.

Fracture risks in patients with atrial fibrillation treated with different oral anticoagulants: a meta-analysis and systematic review

Xie X, Liu Y, Li J, et al. Age Ageing 2022;51:afab264.

Oral anticoagulant use in morbid obesity and post bariatric surgery: a review

Nasser MF, Jabri A, Gandhi S, Rader F. Am J Med 2021;134:1465–75.

Ischemic stroke

Feske SK. Am J Med 2021;134:1457–64.

Advances in stroke: treatments-preventive

Sandset EC, Goldstein LB. Stroke 2022;53:608–10.

Anticoagulation after stroke: persistent uncertainties

Siepen BM, Seiffge DJ, Fischer U. Curr Opin Neurol 2022;35:55–61.

Management of atrial fibrillation in patients 75 years and older: JACC state-of-the-art review

Volgman AS, Nair G, Lyubarova R, et al. J Am Coll Cardiol 2022;79:166–79.

Advances in the management of cardioembolic stroke associated with patent foramen ovale

Mac Grory B, Ohman EM, Feng W, et al. BMJ 2022;376:e063161.

Screening for atrial fibrillation: updated evidence report and systematic review for the US preventive services task force

Kahwati LC, Asher GN, Kadro ZO, et al. JAMA 2022;327:368–83.

Screening for atrial fibrillation

Jin J. JAMA 2022;327:401.

Dabigatran in cardiovascular disease management: a comprehensive review

Javed A, Ajmal M, Wolfson A. World J Cardiol 2021;13:710–9.

Trials

New oral anticoagulant versus vitamin K antagonists for thoracoscopic ablation in patients with persistent atrial fibrillation: a randomized controlled trial

Lee Y, Jeong DS, Ahn J, et al. Semin Thorac Cardiovasc Surg 2023;35:268–74.

Clinical decision support to Optimize Care of patients with Atrial Fibrillation or flutter in the Emergency department: protocol of a stepped-wedge cluster randomized pragmatic trial (O'CAFÉ trial)

Vinson DR, Rauchwerger AS, Karadi CA, et al. Trials 2023;24:246.

Randomized clinical trial to evaluate an atrial fibrillation stroke prevention shared decision‐making pathway

Wang PJ, Lu Y, Mahaffey KW, et al. J Am Heart Assoc 2023;12:e028562.

Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial

Shim CY, Seo J, Kim YJ, et al. J Thorac Cardiovasc Surg 2023;165:58–67.e4.

Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48

Bonaca MP, Antman EM, Cunningham JW, et al. Eur Heart J Cardiovasc Pharmacother 2022;8:695–706.

Effects of dabigatran versus warfarin on 2-year cognitive outcomes in old patients with atrial fibrillation: results from the GIRAF randomized clinical trial

Caramelli B, Yu PC, Cardozo FAM, et al. BMC Med 2022;20:374.

A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study

Reinecke H, Engelbertz C, Bauersachs R, et al. Circulation 2023;147:296–309.

Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial

Pokorney SD, Chertow GM, Al-Khalidi HR, et al. Circulation 2022;146:1735–45.

Early rhythm control in patients with atrial fibrillation and high comorbidity burden

Rillig A, Borof K, Breithardt G, et al. Circulation 2022;146:836–47.

Early versus delayed non-vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation (TIMING): a registry-based randomized controlled noninferiority study

Oldgren J, Åsberg S, Hijazi Z, et al. Circulation 2022;146:1056–66.

Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial

Eckardt L, Sehner S, Suling A, et al. Eur Heart J 2022;43:4127–44.

Rivaroxaban in rheumatic heart disease-associated atrial fibrillation

Connolly SJ, Karthikeyan G, Ntsekhe M, et al. N Engl J Med 2022;387:978–88.

Amiodarone with or without N-acetylcysteine for the prevention of atrial fibrillation after thoracic surgery: a double-blind, randomized trial

Amar D, Zhang H, Chung MK, et al. Anesthesiology 2022;136:916–26.

Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6

Strain WD, Frenkel O, James MA, et al. Stroke 2022;53:2749–57.

Systolic blood pressure and effects of screening for atrial fibrillation with long-term continuous monitoring (a LOOP substudy)

Xing LY, Diederichsen SZ, Højberg S, et al. Hypertension 2022;79:2081–90.

Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial

De Caterina R, Patti G, Westerbergh J, et al. Eur Heart J Cardiovasc Pharmacother 2022;8:227–35.

Apixaban or warfarin and aspirin or placebo after acute coronary syndrome or percutaneous coronary intervention in patients with atrial fibrillation and prior stroke: a post hoc analysis from the AUGUSTUS trial

Bahit MC, Vora AN, Li Z, et al. JAMA Cardiol 2022;7:682–9.

Effect of 15-mg edoxaban on clinical outcomes in 3 age strata in older patients with atrial fibrillation: a prespecified subanalysis of the ELDERCARE–AF randomized clinical trial

Kuroda M, Tamiya E, Nose T, et al. JAMA Cardiol 2022;7:583–90.

Effect of mailing educational material to patients with atrial fibrillation and their clinicians on use of oral anticoagulants: a randomized clinical trial

Pokorney SD, Cocoros N, Al-Khalidi HR, et al. JAMA Netw Open 2022;5:e2214321.

Outcomes and safety of very-low-dose edoxaban in frail patients with atrial fibrillation in the ELDERCARE-AF randomized clinical trial

Akashi S, Oguri M, Ikeno E, et al. JAMA Netw Open 2022;5:e2228500.

RIvaroxaban in mitral stenosis (RISE MS): a pilot randomized clinical trial

Sadeghipour P, Pouraliakbar H, Parsaee M, et al. Int J Cardiol 2022;356:83–6.

Edoxaban versus warfarin in high-risk patients with atrial fibrillation: a comprehensive analysis of high-risk subgroups

Gencer B, Eisen A, Berger D, et al. Am Heart J 2022;247:24–32.

Electronic health record-embedded decision support to reduce stroke risk in patients with atrial fibrillation – study protocol

Eckman MH, Wise R, Knochelmann C, et al. Am Heart J 2022;247:42–54.

The ENHANCE-AF clinical trial to evaluate an atrial fibrillation shared decision-making pathway: rationale and study design

Baykaner T, Pundi K, Lin B, et al. Am Heart J 2022;247:68–75.

Edoxaban-based long-term antithrombotic therapy in patients with atrial fibrillation and stable coronary disease: rationale and design of the randomized EPIC-CAD trial

Cho MS, Kang DY, Oh YS, et al. Am Heart J 2022;247:123–31.

Association between age and outcomes of catheter ablation versus medical therapy for atrial fibrillation: results from the CABANA trial

Bahnson TD, Giczewska A, Mark DB, et al. Circulation 2022;145:796–804.

Screening for atrial fibrillation in older adults at primary care visits: VITAL-AF randomized controlled trial

Lubitz SA, Atlas SJ, Ashburner JM, et al. Circulation 2022;145:946–54.

Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial

Willems S, Borof K, Brandes A, et al. Eur Heart J 2022;43:1219–30.

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Piccini JP, Caso V, Connolly SJ, et al. Lancet 2022;399:1383–90.